Aim: To review economic evaluations of weight loss drugs and compare reported incremental cost-effectiveness ratios (ICERs). Methods: A literature search was conducted for cost-effectiveness (CEAs) and cost-utility analyses (CUAs) of sibutramine, orlistat and rimonabant. Results: Fourteen unique articles were identified (11 CUAs and 3 CEAs; 9 orlistat, 4 sibutramine and 1 rimonabant). All used diet and exercise as comparator, whereas none included indirect costs. Time horizons varied from treatment period only (1-4 years) to 80 years (median 7.5 years). Longer studies modeled effects on diabetes, micro-and macrovascular complications, coronary heart disease and death. Of the CUAs, the median ICER was h 2007 16 000/QALY (quality-adjusted life-year; range 10 000-88 000), with the worst cost-effectiveness when recommended stop rules for non-responding patients were not applied. All studies but three were funded by the manufacturing company, and the median ICER was considerably higher for independent than for sponsored analyses (h62 000 vs h15 000/QALY). However, two of the three independent CUAs did not use recommended stop rules, as compared with one of eight manufacturer-sponsored analyses. The results were most sensitive to assumptions regarding weight loss sustainability and utility per kilogram lost. Side effects and dropout because of reasons other than lack of efficacy were generally not incorporated. Conclusion: Published economic evaluations indicate that orlistat, sibutramine and rimonabant are within the range of what is generally regarded as cost-effective. Uncertainty remains about weight loss sustainability, utility gain associated with weight loss and extrapolations from transient weight loss to long-term health benefits. Modeling of head-to-head comparisons and attrition is needed, as are analyses conducted independently of manufacturing companies.
Introduction
Obesity is associated with increased morbidity, 1 increased mortality [2] [3] [4] and decreased productivity, 5, 6 resulting in major economic consequences for society in the form of both direct 7, 8 and indirect costs. 9 Obesity prevalence has reached 20-30% in many European countries, indicating that the number of patients in need of losing weight is counted in millions in Europe alone. 10, 11 Although surgical treatment results in sustainable weight loss of large magnitude, 12 it is neither feasible nor desirable to provide such treatment to all obese individuals. However, pharmacotherapy combined with lifestyle modification results in lower weight loss, and has been described as expensive. [13] [14] [15] There are currently three registered weight loss compounds in the European Union, namely orlistat (Xenical/ Alli), sibutramine (Reductil/Meridia) and rimonabant (Acomplia/Zimulti). Sibutramine and orlistat have been in the world market for more than 5 and 10 years, respectively. Rimonabant was introduced on the European market in 2006, but has been delayed in the United States because of concerns regarding its association with psychiatric disorders. 15, 16 Orlistat and sibutramine are also associated with side effects, but mainly in the form of gastrointestinal problems (orlistat), and elevations in blood pressure and tachycardia (sibutramine) compared to placebo. Owing to efficacy and safety considerations, the drugs have been licensed for certain subgroups, to be used for a limited time and under medical supervision. In addition, economic considerations have limited the reimbursement of the drugs to a smaller group than the licensed indication permits in several countries. For example, in Sweden, orlistat is reimbursed for patients with BMIX35 kg/m 2 Although a number of cost-effectiveness (CEAs) and costutility analyses (CUAs) of anti-obesity drugs exist, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] no systematic review has been published comparing the features of different studies in any greater detail. Therefore, our aim was to conduct a systematic review of published economic evaluations of the three licensed anti-obesity drugs in the European Union, that is orlistat, sibutramine and rimonabant, and to compare their incremental cost-effectiveness ratios (ICERs).
Methods
A comprehensive literature search of PubMed, CRD databases (NHS EED, DARE and HTA), Cochrane Library and the Tufts database on economic evaluations in health care until 31 May 2008 was conducted. The following search terms were used: (obesity OR obese OR overweight) AND (cost AND (effectiveness OR utility)) AND (orlistat OR sibutramine OR rimonabant OR xenical OR reductil OR acomplia OR alli OR meridia OR zimulti). The search was limited to articles in English. See Appendix 1 for detailed search string.
The following data were recorded from each trial: intervention and comparator, country, cost year, lead author, clinical data used, population and subgroup, time horizon, outcome measure and result, sensitivity analysis range, type of model, funding and perspective. Potential long-term sequelae considered (T2DM and coronary heart disease (CHD)), types of sensitivity analyses (one-way, multi-way and probabilistic) and whether a 'treatment responder approach' was used were also recorded. Information about effects on obesity-related long-term sequelae and assumptions regarding the sustainability of weight loss used in the models were also extracted.
For sibutramine and orlistat, the current treatment recommendations from the European Agency for the Evaluation of Medicinal Products (EMEA) stipulate that patients who have not succeeded in losing 45% of their initial weight after 3 months should be taken off medication. These recommendations are referred to as 'treatment responder approach. ' For comparison of reported ICERs, they were rounded to thousands and converted to euros (h) per quality-adjusted life-year (QALY) by using the average exchange rate for the cost-year used in the study. Thereafter, the value was inflated to 2007 prices using the OECD consumer price index (http://www.stats.oecd.org).
Results
In the first screening process, 22 articles were found. The abstracts were screened and out of the 22 studies, 6 were excluded; 4 were reviews, 34,37-39 1 was a letter 36 and 1 was irrelevant for the study question. 40 Thereafter, the fulltext articles were retrieved and by snowballing from the reference lists, one additional study was found. 41 After review of the full-text articles, three were excluded. One reviewed the CEA from the industry submission, 28 which was also published separately with a minor change in the base case analysis. 21 The other two 27, 33 were reviews of an earlier analysis. 41 The search strategy and elimination of duplicates resulted in a total of 14 articles being included in the systematic review ( Figure 1 ): 9 studies on orlistat, 23 
General characteristics
Four of the studies were from the United Kingdom, 19, 21, 23, 41 four from the United States 21, 22, 26, 30 and the rest from Sweden, 29, 35 Switzerland, 19, 29 Germany, 19, 20 Ireland, 24 Finland, 19 Belgium, 25 Italy 31 and the Netherlands (Table 1) . 32 No study included indirect costs and all, except for three, 30, 32, 41 were conducted or sponsored by the manufacturing company. One study used cost per life-year gained as outcome measure, 25 1 study used cost per event-free life-year gained 26 and 1 study used cost per lb lost, 22 whereas the remaining 11 studies were CUAs using cost/ QALY gained (Table 2) . [19] [20] [21] 23, 24, [29] [30] [31] [32] 35, 41 The median time horizon modeled was 7.5 years (range , and the duration of treatment was 1 year in all but four studies, where it was 2 years 25,30,41 or 4 years 31 (Table 1) .
Subgroups
Six of the orlistat studies modeled 'healthy' overweight or obese patients. 23, 24, 31, 32, 35, 41 One of these also investigated a subgroup with impaired glucose tolerance. 31 An additional three studies investigated patient cohorts with T2DM. 25, 26, 29 One of these studies further subdivided the patients into four groups depending on whether hypertension and/or hypercholesterolemia was present at baseline. 25 Five of the more recent orlistat studies were conducted according Cost-effectiveness of pharmacological anti-obesity treatments M Neovius and K Narbro to EMEA guidelines, 23, 24, 29, 32, 35 improving the ICERs, as nonresponders are taken off the drug shortly after the initiation of therapy and thus stop to incur drug costs. Three of the four identified sibutramine studies used the same modeling framework, but for different countries and with some variations in the underlying data. [19] [20] [21] All three studies focused on the 'healthy obese' without comorbidities at baseline and modeled costs and effects associated with progression to CHD and T2DM, as well as utility associated with weight loss itself over a 5-year time horizon. The fourth study did not use any modeling or quality-of-life (QoL) data, but looked only at weight loss and costs incurred during the treatment year. 22 This fourth study appeared to be the only study with costs collected alongside the randomized controlled trial (RCT) from which effect data were retrieved. The only rimonabant study modeled patients with either a BMI430 kg/m 2 or a BMI427 kg/m 2 with dyslipidemia or hypertension over a 5-year time horizon. 30 No study explicitly modeled patients from different BMI strata, contrasting the indication with stricter reimbursement guidelines, although one study of orlistat investigated different BMI strata in sensitivity analyses (BMI 30/33/36/ 39), finding small differences.
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Sequelae All studies, except the three that looked only at the treatment period, 22, 23, 41 modeled CHD and/or T2DM or related sequelae beyond the treatment period ( Table 2 ). The most recent orlistat study modeled a wide range of obesity-related diseases based on data from several observational studies. 32 Some of the orlistat studies on non-diabetic patients modeled a higher incidence of T2DM in the non-orlistat-treated group based on changes in BMI status caused by the intervention. 24, 35 The studies on diabetics 25 57 All the sibutramine studies modeled CHD using the Framingham risk equations, 70 the increased incidence of T2DM based on the Swedish Obese Subjects (SOS) study 68 and the US Nurses Health Study data. 69 The rimonabant study combined data from the British Regional Heart Study, 78 Nurses Health Study 79, 80 and Physicians Health Study 81 to model T2DM and CHD. Although adverse events were more common in the intervention group in studies of orlistat (gastrointestinal problems), 14, 84 sibutramine (blood pressure and heart rate elevations) 14, 84 and rimonabant (psychiatric events), 15, 16, 84 only one study stated explicitly that potential costs associated with them were included. 21 Other studies stated that the treatment responder approach minimizes costs of adverse events, as those experiencing them usually are lost during the first 3 months, and no costs for additional physician visits were included. Despite documented sizeable dropouts in RCTs in both drug and placebo groups, 84 most studies appeared not to account for patients dropping out of treatment for reasons other than lack of response defined by EMEA guidelines, although it was hard to determine whether and how it was done in some models.
Weight regain
As QoL, morbidity and mortality were coupled to weight loss in most studies, the rate of regain of lost weight was generally found to be a highly influential variable. All studies explicitly stated the assumed rate of regain of lost weight, except for the studies only modeling the treatment period 22, 23, 41 and the study that did not model weight loss per se 31 (Table 2) . For orlistat, a quoted NICE recommendation of using a uniform regain over 3 years was used by four studies, 24, 26, 29, 35 whereas one study applied a 5-year regain 25 Figure 1 Summary of article selection process.
Cost-effectiveness of pharmacological anti-obesity treatments M Neovius and K Narbro Cost-effectiveness of pharmacological anti-obesity treatments M Neovius and K Narbro Cost-effectiveness of pharmacological anti-obesity treatments Cost-effectiveness of pharmacological anti-obesity treatments M Neovius and K Narbro and one assumed that 23% of the weight loss at 1 year would be maintained for life. 32 The sibutramine studies of more than 1 year duration all used the rate of regain documented in the Sibutramine Trial of Obesity Reduction and Maintenance (STORM) study 67 of 0.385 kg/month (CI 95% (95% confidence interval) 0.359-0.411), which resulted in a faster regain of lost weight than 3 years. Catch-up with untreated subjects, experiencing natural history weight gain, was modeled to be reached after 5 years. Similarly, the study of rimonabant used weight regain data from the second year of the RIO North America trial, 75 in which rimonabant-treated patients were re-randomized at 1 year to either placebo or continued drug treatment. The weight regain appeared to be of comparable magnitude as that documented in the STORM trial for sibutramine.
67
Utility Seven of the orlistat and three of the sibutramine studies, as well as the only rimonabant study, were CUAs, incorporating QoL in the calculations ( Table 2 ). As much of the effectiveness difference between the intervention and placebo arms was driven by utility gains associated with weight loss itself, the value assigned per kilogram or BMI unit lost was the most influential variable in several studies. The first of the orlistat studies used a utility gain of 0.181/ year for responders losing more than 10% of their body weight, based on expert judgment. 41 Four of the remaining orlistat studies, 23, 24, 29, 35 as well as the rimonabant study, 30 used utility data estimated by visual analog scales, depicting a utility value of 0.017 and 0.0285 per BMI unit lost for obese without comorbidity and obese diabetics, respectively. 46 The two remaining orlistat studies used a more conservative approach, including only utility/disutility associated with comorbidities. 31, 32 Utility values for T2DM complications and other comorbidities were taken from various sources. All three CUAs of sibutramine used QoL data from RCTs estimated by short form (SF)-36 71, 85 converted by the Brazier algorithm into utility values. Utility multipliers for T2DM and CHD were used to incorporate the lower QoL in patients progressing to T2DM or experiencing a CHD event. A comparison of the utility per kilogram used for the sibutramine studies and the utility per BMI unit used in the orlistat and rimonabant studies revealed that the latter utility estimate used for non-diabetics was approximately 60% higher than the estimate used for sibutramine in three of the four CUAs (0.00375 vs 0.0062). This comparison was based on a conversion factor between BMI and kilogram of 0.36, which was calculated from the weight loss and BMI loss data in the Cochrane review by Padwal et al.
(see Appendix 2).

ICERs
The variation in ICERs for the CUAs in h/QALY is shown in Figure 2 . The median was h 2007 16 000/QALY (range 10 000-88 000). The three CUAs not using a treatment responder approach had higher ICERs than the overall group (median h67 000/QALY; range 21 000-88 000).
30,31,41
The three estimates for T2DM or impaired glucose tolerance subgroups were low (median h16 000/QALY), 29, 31 but two were from the same study employing a very high utility per BMI unit lost 29 as compared with that employed Figure 2 Mean incremental cost-effectiveness ratios (ICERs; h2007/QALY) from cost-utility analyses. Error bars indicate high/low values from sensitivity analyses.
No TRR ¼ EMEA recommended treatment responder approach not used. Studies conducted independent of the manufacturer were on obese subjects without diabetes at baseline.
Cost-effectiveness of pharmacological anti-obesity treatments M Neovius and K Narbro for non-diabetic patients. However, in the study by Iannazzo et al., 31 both obese patients in general and obese patients with impaired glucose tolerance were investigated with the same methodology (not using a treatment responder approach nor modeling utility gains associated with weight loss per se). They found a much more favorable ICER for the impaired glucose tolerance subgroup (h21 000/QALY) as compared with the obese subgroup (h75 000/QALY), when assuming that the drug was not reimbursed. Analyses sponsored by the manufacturer had much more favorable median ICERs than those without sponsorship (h15 000 vs 62 000/QALY), but were also conducted according to a treatment responder approach to a greater extent than the independent analyses (Figure 2) . Major methodological differences existed between studies, complicating comparisons between drugs. All sibutramine studies were using the same framework on 'healthy obese' patients, including a treatment responder approach, and were all sponsored by the manufacturer. For orlistat, a much greater heterogeneity was seen with estimates both for non-diabetic and for diabetic patients, with or without a treatment responder approach, and with or without sponsorship from the manufacturer. The only rimonabant study was on 'healthy obese' subjects, did not use a treatment responder approach and was performed independent of the manufacturer. With these differences in mind, the median ICERs were h28 000, h13 000 and h59 000/QALY for orlistat, sibutramine and rimonabant, respectively.
The study investigating different BMI strata in its sensitivity analysis found small differences in ICERs between BMIs 30/33/36/39 (h16 000/15 000/13 000/12 000/QALY).
35
Sensitivity analyses and discounting One study did not perform any sensitivity analyses, 22 whereas six studies performed only one-way, 19, 20, [23] [24] [25] 29 two performed multi-way 21, 41 and five performed both one-way and probabilistic, 26, 30, 32, 35 or probabilistic only. 31 However, one of the studies performing a probabilistic sensitivity analysis did not mention for which variables distributions were specified. 35 An additional study claimed to have performed a probabilistic sensitivity analysis, but no such results were found. 29 The discount rates applied varied between countries. The Irish, 24 Switzerland and the United Kingdom depending on the study; one study 19 from Switzerland used 5%, whereas the other 29 used 3% for costs and effects in the base case, and one United Kingdom study used 6% for costs and 1.5% for effects, 21 whereas one used 3.5% for both costs and effects, 19 which the Italian study also did. 31 The Dutch study discounted effects at 1.5% and costs at 4.0%. 32 The use of discounting in the earliest study of orlistat was unclear. 41 
Discussion
We reviewed economic evaluations of pharmacotherapies for obesity registered in the European Union, including nine studies of orlistat, four of sibutramine and one of rimonabant. All compared the respective compound combined with diet and exercise with diet and exercise only. In general, the early studies did not extend beyond the treatment year, and were not performed in accordance with current EMEA guidelines (only treating responders past 3 months). The more recent studies generally incorporated effects on long-term sequelae, such as T2DM and CHD, based on extrapolations. Little attention was given to characterize discontinuation in general, as well as discontinuation from adverse events. In all studies using the recommended EMEA treatment algorithm, the ICERs were below or near h50 000/QALY; however, all but one 32 of these were funded by the manufacturing company. To reduce the uncertainty of the cost-effectiveness of weight loss drugs, better data on weight loss sustainability, utility gains associated with weight loss and actual data on effects on long-term sequelae would be useful.
Time horizon
Compared with the early CUAs of pharmacotherapy, several of the more recent studies separately modeled overweight and obese diabetics and non-diabetics, as well as extended the time horizon and modeling assumptions. As clinical trials of weight loss compounds seldom or never are long enough to be able to include harder end points associated with obesity, such as T2DM incidence, CHD events and death, these extensions have the potential to provide a better picture of the economics of the therapies. The study by Iannazzo et al., 31 using 4 years' results from the XENDOS study, 56 was the only one that used actual trial data on the incidence of diabetes. The other studies used weight loss or changes in other metabolic parameters to model risk of diabetes and CHD over time.
In addition, the recommendations of both NICE and other national reimbursement agencies are to model a time horizon so that all costs and effects are included, which often is synonymous with a lifetime perspective. Most studies used 1-or 2-year trial data to extrapolate to 5-or 10-year time horizons. Only van Baal et al. 32 modeled patients over a lifetime. Although longer time horizons theoretically could provide a more accurate picture of costs and health effects of treatment, the increased uncertainty from data constraints is usually large and needs to be thoroughly investigated. For example, the Framingham equations were derived to predict future risk using baseline values, not to determine how temporary changes in these values affect long-term risk, as is the way they have been used in several of the reviewed studies. With time, real-world data may emerge to validate the assumptions made. The treatment duration modeled was 1 year in most studies, whereas durations of 2 or 4 years were also modeled Cost-effectiveness of pharmacological anti-obesity treatments M Neovius and K Narbro by some. As data on X2 years treatment duration are available for all three compounds, 56, 67, 75 further investigation of cost-effectiveness of longer than 1 year treatment duration would be informative. Longer term treatment for responding patients is potentially a more realistic characterization of clinical practice, as obesity is a chronic disease requiring chronic treatment. However, clinical guidelines stipulate time-limited treatment, although it is unclear why anti-obesity treatment should be time limited if patients are tolerating and responding to the drug. In the treatment of other chronic diseases, such as hypertension, such a strategy would be highly questionable.
Comparators
Recommendations from reimbursement agencies also stipulate that relevant comparators should be used. 86 Diet and exercise is a relevant comparator to a weight loss drug, but it is not the only one. Although orlistat, sibutramine and rimonabant differ to some extent in their potential patient recruitment pools because of their differing side effect profiles, a great percentage of patients could be eligible for any of the three. All reviewed studies compared pharmacotherapy combined with diet and exercise against diet and exercise only, but not with other pharmacotherapies for obesity. Although no head-to-head trials exist comparing orlistat and rimonabant, or sibutramine and rimonabant, there are at least eight RCTs directly comparing orlistat and sibutramine. 87 In addition, although the inclusion and exclusion criteria for the RCTs of the three compounds differ in some regard, they are comparable enough for modeling attempts. 13, 14 Consequently, future cost-effectiveness analyses should not only compare the individual drugs against placebo/diet and exercise but also against each other to provide guidance for decision makers and reimbursement agencies. This could help inform recommendations regarding which drug should be used as first-, second-or third-line treatment, given that no contraindications are present. The recent NICE guidance for rimonabant, published after the review period used for this systematic review, recommends rimonabant only after intolerance or lack of response to orlistat and sibutramine, provided that no contraindications exist.
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Uncertain parameter values The most influential parameters in several of the evaluations were the rate of weight regain after the treatment period, 26, 35 and utility associated with weight loss. 21, 28 Several orlistat studies used a NICE recommendation regarding an assumption of uniform weight regain over 3 years. 24, 26, 29, 35 For sibutramine and rimonabant, 2 years' data were used and extrapolated over the remaining of the time horizon in the models. [19] [20] [21] 30 Contrary to the approach in these studies, van Baal et al. assumed that 23% of the weight loss would be maintained in the long run. As weight regain appears to be such an influential parameter on the cost-effectiveness outcomes, it is a relevant task to collect data on weight change after treatment discontinuation, in order to reduce uncertainty in the cost-effectiveness models.
Regarding utility, there appears to be a large discrepancy between the values used in sibutramine vs orlistat and rimonabant studies. Furthermore, the data used were derived from visual analog scales 46 or SF-36, 71, 85 not from more suitable methods such as time trade-off or standard gamble. Better sources of data on utility associated with weight loss would strengthen future analyses, and possibly increase comparability between studies.
Subgroups
In some countries, the compounds are reimbursed only for morbidly obese (BMIX35 kg/m 2 ) and those with a BMIX28 kg/m 2 with T2DM or dyslipidemia. 35 No studies of sibutramine or rimonabant investigated diabetic and nondiabetic subgroups separately, whereas this was the case for orlistat. 25, 26, 29 However, the economic basis for the cutoff of BMI 35 vs the cutoff of BMI 30 in the indication was not investigated by any of the studies.
Discontinuation rates and adverse events
Although attrition has been very high in orlistat, sibutramine and rimonabant studies, 13, 14, 84 this was not accounted for or unclear in all of the studies. Although many patients are lost at 3 months when using a treatment responder approach, it is likely that not all dropouts have occurred at that time. Furthermore, despite the fact that adverse events have drawn considerable attention historically for weight loss drugs in general, 88 and also recently for orlistat, sibutramine and especially for rimonabant, 15, 16 no study was explicitly taking discontinuation due to adverse events into account.
Influence of the funding source Only 3 30, 32, 41 of the 14 economic evaluations were performed without association to the manufacturing company, and these displayed a higher median ICER than sponsored studies, indicating an association between funding source and outcome. However, only one of the three independent studies used the EMEA recommended treatment responder approach in the modeling compared with seven of the eight manufacturer-sponsored analyses. As the use of a treatment responder approach is associated with improved cost-effectiveness, it is hard to disentangle the effect of company sponsorship and the use of treatment responder approach.
Summary
In summary, the more recent economic evaluations have adopted longer time horizons and are generally performed according to treatment guidelines. Close to all resulting ICERs were within what is often regarded to be cost-effective (oh50 000), although the great majority of analyses was also sponsored or conducted by the manufacturers. Uncertainty still remains about the utility gain associated with weight loss, and rate of weight regain, and
Cost-effectiveness of pharmacological anti-obesity treatments M Neovius and K Narbro more research is hence called for, as these are highly influential parameters. Furthermore, there is a need for further research about potential long-term health effects to validate extrapolations of the effect of transient weight loss, analyses on subgroups based on BMI status and comorbidities and attempts to model head-to-head comparisons. Finally, adverse events and the high discontinuation rates observed in trials need to be addressed explicitly.
